JR
Therapeutic Areas
AbbVie Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Skyrizi (risankizumab) | Crohn's Disease (pediatric) | Phase 3 |
| Rinvoq (upadacitinib) | Giant Cell Arteritis | Phase 3 |
| Teliso-V (telisotuzumab vedotin) | Non-Small Cell Lung Cancer (c-Met+) | Phase 3 |
| ABBV-951 | Parkinson's Disease | Approved |
| ABBV-383 | Relapsed/Refractory Multiple Myeloma | Phase 1 |
| ABBV-400 | Advanced Solid Tumors | Phase 1 |
| ABBV-154 | Rheumatoid Arthritis | Phase 2 |
| ABBV-647 | Prostate Cancer | Phase 1 |
Leadership Team at AbbVie
RA
Richard A. Gonzalez
Chairman and Chief Executive Officer
RA
Robert A. Michael
President and Chief Operating Officer
TJ
Thomas J. Hudson
SVP, Chief Scientific Officer
ST
Scott T. Reents
SVP, Chief Financial Officer
PC
Perry C. Siatis
SVP, General Counsel
AS
Azita Saleki-Gerhardt
EVP, Chief Operations Officer